Logo Lucerna-Chem
+41 41 420 9636

Regulatory Status

Article Status


Catalog Number Pack Size List Price* Quantity
HY-13463-50MG 50 mg Inquire
HY-13463-5MG 5 mg Inquire
HY-13463-10MG 10 mg Inquire
HY-13463-10MMO 10 mM * 1 mL Inquire
HY-13463-100MG 100 mg Inquire

* CHF, excl. 7.7% VAT and shipping costs

Product Description

AKR-501; E5501; YM477
Avatrombopag (AKR-501) is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC50=3.3 nM). Avatrombopag mimics the biological activities of TPO. Avatrombopag increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A.

Category Biochemicals
Supplier MedChem Express
Application COVID-19-immunoregulation
Regulatory Status RUO
Format Solubility: DMSO : ≥ 32 mg/mL (49.26 mM)
Grade Clinical information: Launched
Molecular Formula C29H34Cl2N6O3S2
Molecular Weight 649.65
CAS-Number [570406-98-3]
Storage Conditions Please store the product under the recommended conditions in the Certificate of Analysis.
Product Line Research
Tech. Data Sheet View datasheet
Link To Supplier http://www.medchemexpress.com
Material Safety Data Sheet Download PDF
Call us

Customer Support
T +41 41 420 96 36
F +41 41 420 96 56

Business Hours
From Monday through Friday
08:00 – 12:00
13:00 – 17:00

Ask us

Technical Support

Business Development

Postal address
Lucerna-Chem AG
Abendweg 18
CH-6006 Luzern


If you have already subscribed to our newsletter and would like to update your details or cancel it, please click here.

© Copyright 2021 Lucerna-Chem AG, Switzerland